HLA antibodies are typically produced after exposure to transplanted tissue, pregnancy, and blood products. Sensitization delays access to transplantation and preclude utilization of donor organs. Infections and vaccinations have also been reported to result in HLA antibody formation. It is not known if patients develop HLA antibodies after infection with SARS-CoV-2. Here we analyzed a series of eighteen patients waiting for kidney transplantation who had symptomatic COVID-19 disease and recovered. None of the patients in this initial series developed de novo HLA antibodies. Notably, there was no increase in preexisting HLA antibodies in four highly sensitized patients with a CPRA > 80%. These preliminary data suggest that there may not be a need to repeat HLA antibody testing or perform a physical crossmatch on admission serum before kidney transplant for COVID-19 recovered patients. Data from a large number of patients with different demographics needed.

HLA 抗体通常在接触移植组织、怀孕和血液制品后产生。致敏延迟了移植的可及性并妨碍了供体器官的利用。据报道，感染和疫苗接种也会导致 HLA 抗体的形成。目前尚不清楚患者在感染 SARS-CoV-2 后是否会产生 HLA 抗体。在这里，我们分析了一系列等待肾移植的 18 名患有 COVID-19 症状并康复的患者。在这个最初的系列中没有一个病人从头发展HLA 抗体。值得注意的是，在 4 名 CPRA > 80% 的高度敏感患者中，预先存在的 HLA 抗体没有增加。这些初步数据表明，对于 COVID-19 康复的患者，在肾移植前可能不需要重复 HLA 抗体检测或对入院血清进行物理交叉配型。需要来自具有不同人口统计特征的大量患者的数据。